Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0061323. doi: 10.1128/aac.00613-23. Epub 2023 Oct 3.

Abstract

Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.

Keywords: bronchoalveolar lavage; invasive fungal infection; isavuconazole; lung transplant; tissue penetration.

MeSH terms

  • Bronchoalveolar Lavage Fluid
  • Humans
  • Lung* / surgery
  • Transplant Recipients*
  • Triazoles / pharmacokinetics

Substances

  • isavuconazole
  • Triazoles